ImmuneBridge

Building the next generation of cell therapies

San Francisco, United States · Founded 2022

Employees
1–10
Founded
2022
Business Model
B2B
Last Round
Series A
Rounds
2

About

ImmuneBridge develops an integrated platform for designing and manufacturing next-generation cell therapies using umbilical cord blood-derived hematopoietic stem cells. The company's proprietary expansion technology amplifies immune stem cells while maintaining full multipotency, enabling rapid discovery and scalable production of natural killer (NK) cell therapies for hematologic malignancies and solid tumors. ImmuneBridge's machine learning-powered donor screening and manufacturing platform addresses key universal challenges in cell therapy development, targeting both academic and industry partners while building an internal pipeline of proprietary therapies.

Summary

ImmuneBridge is a Life Sciences company based in San Francisco, United States, founded in 2022. Investors include LongGame, 10X Capital and Calm Ventures.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries A

Sign up to see all 2 rounds

Series A through Seed — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

ImmuneBridge on Indexed.vc
<a href="https://indexed.vc/companies/immunebridge"><img src="https://indexed.vc/api/badge/company/immunebridge" alt="ImmuneBridge on Indexed.vc" width="260" height="76" /></a>